Skip to Primary Navigation

Skip to main content

FDA launches expedited IND pilot to bolster American leadership

A photo of Acting FDA Commissioner Kyle Diamantis speaking at a press conference.
Acting FDA Commissioner Kyle Diamantis. Photo: Win McNamee/Getty Images
Kevin Kinsella's profile image

Kevin Kinsella

2 min read

Pilot program aims to accelerate taking a new drug to first-in-human trials but industry groups have raised questions about the role of QRIs.

Expecting to close clinical trial timelines and eliminate regulatory hurdles, the US Food and Drug Administration (FDA) has announced the final design of a new drug pilot program.

The Expedited Investigational New Drug (IND) Pilot seeks to expedite the time it takes from identifying a drug to beginning a first-in-human

, , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience